FOLH1 and metastatic prostate carcinoma: Using this strategy, 225Ac-PSMA-617, which has been an effective treatment for men with metastatic prostate cancer, which was previously believed to be refractory to conventional chemotherapies and standard of care radiotherapy, has been developed.